Enzo Biochem, Inc.
ENZB · OTC
7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | |
|---|---|---|---|---|
| Revenue | $31,907 | $31,061 | $107,071 | $117,731 |
| % Growth | 2.7% | -71% | -9.1% | – |
| Cost of Goods Sold | $17,275 | $19,495 | $65,104 | $64,154 |
| Gross Profit | $14,632 | $11,566 | $41,967 | $53,577 |
| % Margin | 45.9% | 37.2% | 39.2% | 45.5% |
| R&D Expenses | $2,642 | $3,904 | $3,767 | $3,252 |
| G&A Expenses | $24,355 | $27,202 | $53,707 | $44,905 |
| SG&A Expenses | $24,355 | $27,202 | $53,707 | $44,905 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,632 | $0 | $0 | $0 |
| Operating Expenses | $24,365 | $31,106 | $57,474 | $48,157 |
| Operating Income | -$9,817 | -$24,736 | -$15,507 | $9,878 |
| % Margin | -30.8% | -79.6% | -14.5% | 8.4% |
| Other Income/Exp. Net | $0 | -$286 | -$3,312 | $7,183 |
| Pre-Tax Income | -$9,817 | -$25,022 | -$18,261 | $7,875 |
| Tax Expense | $0 | $0 | $4,317 | $0 |
| Net Income | -$26,078 | $20,288 | -$22,578 | $3,425 |
| % Margin | -81.7% | 65.3% | -21.1% | 2.9% |
| EPS | -0.51 | -1.27 | -0.46 | 0.071 |
| % Growth | 59.8% | -176.1% | -747% | – |
| EPS Diluted | -0.51 | -1.27 | -0.46 | 0.071 |
| Weighted Avg Shares Out | 50,902 | 49,160 | 48,594 | 48,191 |
| Weighted Avg Shares Out Dil | 50,902 | 49,160 | 48,594 | 48,325 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,538 | $277 | $178 | $8 |
| Interest Expense | $197 | $1,399 | $0 | $0 |
| Depreciation & Amortization | $1,272 | $2,682 | $2,827 | $2,653 |
| EBITDA | -$8,348 | -$22,340 | -$15,007 | $3,345 |
| % Margin | -26.2% | -71.9% | -14% | 2.8% |